NCCN Guidelines® Insights - Prostate Cancer Early Detection, Version 1.2023
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically signiﬁcant prostate cancer and minimize the detection of indolent disease.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Prostate Cancer Early Detection
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate Cancer Early Detection
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Individuals Who Provided Content Development and/or Authorship Assistance
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Kelvin A. Moses, MD, PhD, Panel Chair
Marc Dall’Era, MD, Panel Member
Eric Kauffman, MD, Panel Member
Ryan A. Berardi, MSc, Guidelines Layout Specialist, NCCN
Deborah A. Freedman-Cass, PhD, Manager, Guidelines Processes, NCCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Preston C. Sprenkle, MD, Panel Vice-Chair, has disclosed serving as a scientific advisor for Profound Medical Corp.
Sigrid V. Carlsson, MD, PhD, MPH, Panel Member, has disclosed receiving consulting fees from Ipsen.
Jonathan I. Epstein, MD, Panel Member, has disclosed serving as a scientific advisor for Biogensis, Inc.; receiving consulting fees from Dianon Systems, Inc.; having equity interest/stock options in PathAI; and receiving non-royalty payments from UroGen Pharma.
David Jarrard, MD, Panel Member, has disclosed serving as a scientific advisor for Gregor Diagnostics Inc.
Adam S. Kibel, MD, Panel Member, has disclosed serving as a scientific advisor for Bayer HealthCare, Cellvax Therapeutics, Exelixis, Inc., Janssen Pharmaceutica Products, LP, Myovant Sciences, ProFound Therapeutics, and Roche Laboratories, Inc.; and serving on a data safety monitoring board for Bristol-Myers Squibb Company and Candel Therapeutics.
Tyler M. Seibert, MD, PhD, Panel Member, has disclosed receiving grant/research support from General Electric; serving as a scientific advisor for CorTechs Labs; having equity interest/stock options in CorTechs Labs; and receiving honoraria from Varian Medical Systems, Inc.
Geoffrey Sonn, MD, Panel Member, has disclosed receiving consulting fees from Auris Health, Inc.; and serving as a scientific advisor for miR Scientific.
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-23-003-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 10, 2024. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation